INTRODUCTION {#S1}
============

Genital mycoplasmas (*Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma genitalium* and *Mycoplasma hominis*) are bacteria found in the placenta and/or embryo in pregnant women. They can cause ascending infection after rupture of membranes and severe problems such as premature membrane rupture, preterm labour, miscarriage, postpartum fever, chorioamnionitis, and infection transmission to the newborn infant \[[@ref1]-[@ref5]\]. Several studies have reported greater success of fertilisation by assisted reproductive techniques (ART) in couples who were not infected by *Ureaplasma* spp. \[[@ref6], [@ref7]\]. Increased semen quality and better ART results have also been observed in couples infected by mycoplasmas who were treated with specific antibiotics to eradicate the infection \[[@ref8], [@ref9]\]. Moreover, the impact on female reproduction and the health of the fetus and newborn that can have genital mycoplasma suggests a role for routine screening and treatment before undergoing infertility treatment \[[@ref10]-[@ref12]\]. It therefore seems recommendable to avoid the use of semen contaminated/infected with mycoplasmas in ART procedures. However, currently used procedures for selecting and washing spermatozoa prior to fertilisation do not ensure eradication of these bacteria \[[@ref13]\].

With the advent of highly sensitive and specific nucleic acid amplification technics, more accurate estimate of the prevalence of genital mycoplasma as well as the control of the efficacy of the antibiotic treatment can be determined.

This study presents the results obtained after screening for genital mycoplasmas in urine using amplification by real-time polymerase chain reaction (RT-PCR) in patients enrolled in the assisted human reproduction program at University Hospital Complex of Santiago (CHUS), in Santiago de Compostela, Spain.

MATERIALS AND METHODS {#S2}
=====================

**Patients**. This study included couples enrolled in the assisted human reproduction program carried out by the Assisted Human Reproduction Unit at CHUS during 2016. Couples provided their informed consent after the study was approved by the competent Research Ethics Committee and by the hospital's management (reference number 2015/493). The screening for genital mycoplasmas was performed in male urine. In positive cases, both members of the couple received specific antibiotic therapy and had a post-treatment microbiological test. Couples were asked to use protection (condoms) during sexual intercourse for 7-14 days after initiating the treatment. Both members of the couple had a microbiological test 3-4 weeks after completing the treatment. Couples failing antibiotic treatment were prescribed alternative antibiotics until both members had negative post-therapy microbiological tests. No patient was on antibiotic treatment at least, three months prior to collection of the sample. As part of the study protocol prior to *in vitro* fecundation, all male patients were screened for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in the same urine sample used for mycoplasma detection.

**Samples**. The first fraction of urine (10-15 mL) was collected from males after at least 2 hours without urinating. Urine was collected under the same conditions for the post-treatment tests in female patients.

**Determination of** ***M*.** ***genitalium**, M*.** ***hominis**, U*.** ***ure**-*** ***alyticum*, and** ***U*.** ***parvum***. Genital mycoplasma screening was performed using real-time PCR with LightMix *Mycoplasma gen/hom Ureaplasma* (Roche, Switzerland) in accordance with the manufacturer's instructions. Briefly, a 224 or 129 bp fragment of the glyceraldehyde-3-phosphate dehydrogenase (gap) gene for *M. genitalium* or *M. hominis*, respectively, was amplified with specific primers detected with labelled probes, identified by melting curve analysis. In the same way, a 187 bp long fragment of 16S RNA gene was applied for *U. urealyticum*. This kit detects also *U. urealyticum* Biotype 1 (*U. parvum*) according to manufacturer´s information. The sensitivity of the test is 10 copies/ mL.

Nucleic acids were extracted previously using the MagnaPure Compact system (Roche, Switzerland) after concentrating the sample by centrifuging 2 mL of urine for 20 minutes at 14,000g \[[@ref14]\]. After discarding the supernatant, 200 μL of the re-suspended sediment were used to load the extraction system.

**Antibiotic treatment to eradicate genital colonisation**. Any positive PCR finding was treated with azithromycin or doxycycline. Quinolones were used when first line treatment failed.

**Statistical analysis**. All statistical analyses were carried out using SPSS v. 20.0 (IBM Corp., Armonk, NY). Statistical significance was set at *p*\< 0.05.

RESULTS {#S3}
=======

A total of 205 couples were enrolled in the study. The age range was 24 to 54 years in men and 23 to 39 in women, with a median age of 36 years for men and 35 years for women. Most men were Caucasian (*n*= 201). Other ethnic groups were American (*n*= 2) and Gypsy (*n*= 2).

A total of 33 (16.1%) males tested positive by real-time PCR for one or more mycoplasmas: *U. urealyticum* 15.1% (*n*= 31) and *M. hominis* 3.9% (*n*= 8), with 6 (2.9%) cases of coinfection with both microorganisms. No sample proved positive for *M. genitalium*.

Initial treatment for *Ureaplasma spp*. was azithromycin in the first 12 couples studied and doxycycline in the remaining 19 couples. [Table 1](#T1){ref-type="table"} shows post-treatment test results for the cases positive for *U. urealyticum*. Treatment failed in 16 patients (11 females, 1 male, and 2 couples), including 12 patients treated with a single oral dose of azithromycin 1 g and 4 patients treated with doxycycline 100 mg/12h p.o. for 7 days. One of the couples (couple \# 61) who tested negative for *U. urealyticum* after initial treatment with doxycycline remained colonised by *M. hominis* and was treated with moxifloxacin (moxifloxacin 400 mg p.o. for 7 days).

###### 

Number of therapeutic failures depending on the antibiotic used for initial treatment in patients positive for *U. urealyticum*

                 Men   Women   Couples
  -------------- ----- ------- ---------
  Azithromycin   1     8       3
  Doxycycline    0     3       1

[Table 2](#T2){ref-type="table"} shows the results of subsequent treatments where real-time PCR tested positive for *U. urealyticum* following a second antibiotic cycle administered after failure of the initial treatment. One of the 12 couples who failed treatment with azithromycin withdrew from the program. The remaining couples were treated with doxycycline 100 mg/12h p.o. for 7 days. There was only one case of therapeutic failure, which was treated alternatively with levofloxacin (500 mg/day, 7 days). As the woman remained positive, she was prescribed vaginal clindamycin 100 mg/day for 3 days. Her post-treatment test was negative.

###### 

Antibiotics used against Ureaplasma spp. and post-treatment real-time PCR success test

  ------------------------------------------------------------------------------------------------------------------------------------------
  1st treatment   2nd treatment   Couple Id.    RT-PCR\          3rd treatment             RT-PCR\          4th treatment   RT-PCR\
                                                post-treatment                             post-treatment                   post-treatment
  --------------- --------------- ------------- ---------------- ------------------------- ---------------- --------------- ----------------
  Azithromycin    No              9                                                                                         

  Azithromycin    Doxycyclin      10            Positive         Levofloxacin              Positive         Clindamycin     Negative

  12              Negative                                                                                                  

  25              Negative                                                                                                  

  28              Negative                                                                                                  

  29              Negative                                                                                                  

  31              Negative                                                                                                  

  36              Negative                                                                                                  

  39              Negative                                                                                                  

  43              Negative                                                                                                  

  46              Negative                                                                                                  

  48              Negative                                                                                                  

  Doxycyclin      Levofloxacin    104           Negative         Moxifloxacin^a^           Negative                         

  106             Negative                                                                                                  

  130             Negative                                                                                                  

  159             Positive        Clindamycin   Positive         Clindamycin + probiotic   Positive                         
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^For M. hominis eradication.

Doxycycline proved ineffective in 4 of the 19 couples treated initially. In these cases, levofloxacin (500 mg/day, 7 days) was used as an alternative. Only one patient remained PCR-positive for *U. urealyticum*. This patient was then treated with vaginal clindamycin 100 mg/day for 3 days; she required a second course combined with a vaginal probiotic, but she still tested positive.

One of the couples who were successfully treated with levofloxacin initially for *U. urealyticum* required further treatment with moxifloxacin 400 mg p.o. for 7 days as *M. hominis* was detected in the post-treatment test (couple \# 104).

The cases of *M. hominis* infection (6/7 in coinfection, 86%) were treated with azithromycin (first 2 couples with coinfection with *Ureaplasma spp*.) and doxycycline (the remaining couples). Treatments failed in 3 patients both them (of whom 2 were members of the same couple) ([table 3](#T3){ref-type="table"}).

###### 

Number of therapeutic failures depending on the antibiotic used for initial treatment in patients positive for M. hominis

                 Men   Women   Couples
  -------------- ----- ------- ---------
  Azithromycin   0     1       1
  Doxycycline    0     1       1

The statistical analysis showed that the response to treatment was poorer among women (*p*\< 0.01). In addition, azithromycin in single-dose regime was significantly less efficient as compared to doxycycline (*p*\< 0.01) in both men and women.

Treatment efficacy was independent of age. However, the age range was too small to observe significant differences.

DISCUSSION {#S4}
==========

*M. hominis* and *Ureaplasma* spp. infections are associated with serious problems during pregnancy (chorioamnionitis, premature rupture of membranes, preterm labour, miscarriage during the last trimester of pregnancy) and/or severe infection in the newborn (bronchopulmonary dysplasia, chronic lung infection, intraventricular cerebral haemorrhage) \[[@ref15], [@ref16]\]. There is evidence that the use of semen infected with *Ureaplasma spp*. for *in vitro* fertilisation (IVF) reduces the rate of pregnancies by embryo transfer \[[@ref6]\] and increases no-pregnancy \[[@ref5]\] and miscarriage rates \[[@ref6], [@ref7], [@ref10], [@ref14], [@ref17]\]. On the other hand, the washing procedures used for semen preparation prior to IVF are not always efficient to eliminate mycoplasmas, as these may remain adhered to the surface of spermatozoa, negatively affecting their quality \[[@ref13], [@ref18], [@ref19]\]. In this context, mycoplasma screening in urine samples and subsequent eradication with antibiotic treatment may provide considerable benefits in the ART protocol. Molecular techniques such as real-time PCR are highly valuable diagnostic tools as they provide significant time reductions compared to conventional cultures, are not affected by previous antibiotic use and have much higher sensitivity \[[@ref20]\]. Our study found that 15.1% of the males were colonised by *Ureaplasma* spp. and 3.9% by *M. hominis* (practically all of whom were coinfected with *Ureaplasma* spp.). These figures are somewhat lower than reported in earlier studies, in which colonisation by *Ureaplasma* spp. also prevailed over *M. hominis* \[[@ref21]-[@ref24]\]. Nevertheless, a high variability on genital mycoplasma prevalence has been reported in part due to geographical and methodological differences \[[@ref25]\]. Unlike other publications which report rates of up to 5% \[[@ref21], [@ref26]\], there were no positive cases of *M. genitalium* in our patients. This could be explained because it's a population with a median age above 35-yearold (some studies report decreasing rates of colonisation by *M. hominis* with age \[[@ref27]\], asymptomatic and, possibly, more conservative sexual behaviour.

Besides the benefits that the eradication of genital mycoplasma can have on the success of assisted reproduction, as already mentioned previously, it was also been shown that pre-emptive antibiotic therapy of genital mycoplasma in colonized pregnant women might represent a beneficial strategy to reduce premature labour and neonatal complications \[[@ref28]\].

According to the recommendations of therapeutic guidelines, macrolides are the treatment of choice for *Ureaplasma* spp. infections, with doxycycline or levofloxacin as alternatives. For *M. hominis*, the treatment of choice is doxycycline, with quinolones as an alternative \[[@ref29], [@ref30]\]. As recommended in these guidelines and taking into account the treatment schedules used in studies in colonized women \[[@ref21]\], azithromycin 1g/ day single-dose was used to eradicate *Ureaplasma* spp. in both members of the couple when the male was positive. In addition to being a first-line option, the azithromycin regime simplifies treatment compliance. For the same reason, azithromycin was also used in cases of *Ureaplasma/M. hominis* coinfection. In several studies, azithromycin is reported to be a highly effective antibiotic against *Ureaplasma* spp., with a very low percentage of resistant strains \[[@ref31]-[@ref33]\]. However, the *in vivo* results obtained in our series using the treatment recommended for sexually transmitted infections (1 g single dose; [www.vademecum.es](http://www.vademecum.es)) revealed the low efficacy of this macrolide. For this reason, after the initial results, doxycycline was used as the first choice (100 mg b.i.d. p.o., 7 days). Some reports have demonstrated that a single dose of azithromycin is less efficient than azithromycin used over longer periods \[[@ref34]\], and this could be the reason behind its low efficacy in our series. Possibly, also could contribute its bacteriostatic mechanisms and less efficacy at low pH. Interestingly, we have also observed a higher rate of antibiotic failure against *Ureaplasma* spp. in women, as compared to men, and this difference was statistically significant (*p*\< 0.01) for azithromycin. Fluoroquinolones (levofloxacin and moxifloxacin) were used as the therapeutic alternative where doxycycline did not eradicate colonisation by genital mycoplasmas. Levofloxacin was ineffective in one couple colonised by *Ureaplasma spp*. and in another couple with *M. hominis* coinfection. Levofloxacin has been suggested as an effective antimicrobial agent against *Ureaplasma* spp. and *M. hominis* \[[@ref35]\], but our results do not support this, as therapeutic failure occurred in 40% of patients treated with levofloxacin. Nevertheless, in view of the small number of cases, we cannot draw any firm conclusions in this regard. Moxifloxacin has been reported to be a powerful antibiotic against *M. hominis* \[[@ref35]\] and indeed, it was a successful alternative in our series for one couple who had failed levofloxacin.

Clindamycin represent a potential well tolerated treatment for unresolved mycoplasma infections after treatment with tetracyclines and macrolides \[[@ref4], [@ref5]\]. In fact, this antibiotic is commonly used to treat bacterial vaginosis involving *M. hominis*. Although *Ureaplasma* spp. are considered intrinsically resistant to lincosamides, given the low percentage of sensitive strains \[[@ref35], [@ref36]\], we decided to use clindamycin as a third-line treatment in women showing therapeutic failure with azithromycin, doxycycline and/or levofloxacin, as it can be administered in vaginal suppositories, resulting in high local drug concentrations. Indeed, eradication of *Ureaplasma* spp. was achieved in one case. More assays are necessary to know the effect of probiotics on the success of the antibiotic treatments.

Treatment efficacy was independent of age, even though the age range was too small to observe significant differences.

Using mycoplasma-free semen we could replace intracytoplasmic microinjection by conventional "in vitro" fecundation in 7,6% of the cases (from 3% to 10,6%) which means cost savings of 7% for each case.

In summary, we consider that genital mycoplasma routine screening could be useful in order to increase the quality of semen which could simplify the *in vitro* fertilisation procedures and raise the success rate of embryo implantation. When antibiotic treatment is necessary, real-time PCR significantly reduces time to initiation of treatment and can be used to assess its efficacy. Doxycycline was more efficacious than azithromycin single-dose regime in eliminate genital mycoplasma colonization. On the other hand, eradication of genital mycoplasmas prior to gestation can avoid possible adverse effects on pregnancy, fetus or the newborn, so, according to the opinion of other authors, as genital mycoplasma colonization of cervix is strongly associated with adverse effects as placenta previa, before a planned pregnancy, eradication of this microorganisms is necessary to prevent pregnancy negative outcomes. In addition, eradication of genital mycoplasma allows, in most cases, to use conventional *in vitro* fecundation technics instead of intracytoplasmic microinjection which is more laborious, complex and expensive.

In the case of patients who do not eliminate colonization in the first treatment regime, the benefit of initiating successive alternative antibiotic treatments is debatable due to delayed onset of fertilization and the possible undesirable effects on the vaginal microbiota that seems to play an important role in relation to female fertility \[[@ref37], [@ref38]\].
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